Very cheap Sp at this level, page-6

Look at the fundamentals.

$100M cash equivalents.

$50M NPAT a year.

Current MC of $850M. Less cash is MC of $750M.

PE of 15 at current prices.

Anyways this is only one trial result with end point similar to last line of treatment.
Besides the enhanced quality of life.

Marketing 101 there are 4 Ps. Product, Price, Placement and Promotion.

So product has different features the standard, not sure about SIRT vs conventional pricing, then come promotion which Sirtex probability has greater sales and marketing given its a focused product company. This result would be communicated and used as an alternative which is better on different grounds than 1-2 months of life.

Quality of life not duration. Is the key message here but novices do not see it.